Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company, has successfully closed its upsized public offering, raising $201.2 million in gross proceeds. The offering included 9,562,500 ordinary shares (including the full exercise of underwriters' option for 1,312,500 additional shares) and pre-funded warrants to purchase 500,000 ordinary shares.

The offering was managed by a syndicate of investment banks including Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers. The securities were offered through an effective shelf registration statement previously filed with the SEC.

Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company focused on bradykinin-mediated diseases, has announced the pricing of an upsized public offering totaling $175 million. The offering consists of 8,250,000 ordinary shares priced at $20.00 per share and 500,000 pre-funded warrants at $19.99 per warrant.

The company has granted underwriters a 30-day option to purchase up to 1,312,500 additional ordinary shares. The offering, expected to close around July 24, 2025, is being managed by Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers.

Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company focused on bradykinin-mediated diseases, has announced a proposed public offering of $150 million in ordinary shares. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares.

The proceeds will fund research and development for late-stage clinical programs, establish a U.S. sales and marketing team, and support working capital needs. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are serving as joint book-running managers for the offering.

Pharvaris (Nasdaq: PHVS) has updated the timeline for topline data from its RAPIDe-3 pivotal Phase 3 study of deucrictibant immediate-release (IR) capsule for hereditary angioedema (HAE) attacks. The company now expects to announce results in Q4 2025, with plans to submit a New Drug Application (NDA) to the FDA in 1H 2026.

The RAPIDe-3 study is evaluating a 20 mg single-capsule oral dose in approximately 120 participants aged 12 and older with HAE. The trial includes patients with C1 inhibitor deficiency and normal C1INH. The primary endpoint focuses on time to onset of symptom relief, with secondary endpoints including time to End of Progression, substantial symptom relief, and complete symptom resolution.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, will present multiple clinical trial results for deucrictibant, their oral bradykinin B2 receptor antagonist for treating hereditary angioedema (HAE), at the upcoming 2025 US HAEA National Summit in Baltimore.

The presentations include six poster sessions scheduled for July 11, covering long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies, quality of life improvements, CHAPTER-3 Phase 3 trial design, durability of response, and comparison with standard of care. All posters will be available on the company's investor relations website.

Pharvaris presented comprehensive data at EAACI Congress 2025 showcasing the potential of deucrictibant, their oral bradykinin B2 receptor antagonist, for treating and preventing bradykinin-mediated angioedema attacks. Key findings from multiple studies demonstrated deucrictibant's efficacy: The CHAPTER-1 open-label extension study showed sustained attack reduction and improved quality of life, while the RAPIDe-2 extension study revealed a median time to symptom relief of 1.1 hours, with 97.8% of attacks achieving relief by 12 hours. Notably, 89.2% of attacks were resolved with a single dose. For upper airway attacks, 92.9% were effectively treated with one dose. The company also presented data on their novel kinin biomarker assay for better diagnosis of bradykinin-mediated conditions and insights from their AAE-C1INH research, where no approved therapies currently exist.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), has scheduled its annual general meeting of shareholders. The meeting will take place on June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). Shareholders can access all relevant meeting documents and information in the "Investors" section of Pharvaris' website under "Events & Presentations" and on the SEC's website. Interested shareholders must register to attend as outlined in the meeting notice and agenda.

Pharvaris (PHVS) presented promising data for deucrictibant in treating bradykinin-mediated angioedema at the 14th C1-Inhibitor Deficiency Workshop. The drug showed strong efficacy in both prophylactic and on-demand treatment settings. In prophylaxis, long-term data revealed sustained attack rate reduction for over 18 months, with maintained quality of life improvements. The new extended-release (XR) formulation demonstrated 24-hour therapeutic coverage supporting once-daily dosing. For on-demand treatment, 95-100% of attacks showed durable response without symptom reoccurrence after a single dose, with median symptom relief onset of 1.1 hours. Notably, deucrictibant effectively treated upper airway attacks with 92.9% requiring only one dose. The company also validated a novel biomarker assay for bradykinin-mediated angioedema, potentially expanding treatment opportunities.

Pharvaris (PHVS) has announced multiple presentations of clinical data for deucrictibant at three major medical conferences in May-June 2025. The presentations will take place at the 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, the 2025 Eastern Allergy Conference in Palm Beach, and the EAACI Congress 2025 in Glasgow. Key presentations focus on deucrictibant's long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies for both prophylaxis and treatment of hereditary angioedema (HAE) attacks. Notable topics include biomarker data, quality of life improvements, pharmacokinetics of the XR tablet formulation, and the CHAPTER-3 Phase 3 trial design. The company will make all presentation materials available on their investor relations website.